#phaseii — Public Fediverse posts

https://www.europesays.com/ch/30458/ Genentech petrelintide sheds 10.7% weight in Phase II #ClinicalTrial #Genentech #Obesity #overweight #petrelintide #PhaseII #RHHBY #Roche #WeightLoss

SynAct Pharma Completes Recruitment for ADVANCE

SynAct Pharma has met the recruitment target for its Phase II ADVANCE study of resomelagon. Once the final patient completes the 12-week period and follow-up, database lock will commence at over 30 clinics. The trial evaluates dose-dependent safety and efficacy while maintaining a favorable risk/benefit profile.

#SynActPharma #biotech #PhaseII #clinicaltrials

NMD Pharma Reports Topline Phase IIa Results

NMD Pharma announced data from the SYNAPSE-CMT study evaluating ignaseclant in Charcot-Marie-Tooth disease types 1 and 2. The CIC-1 inhibitor showed consistent functional improvements regarding muscle strength, motor performance, and patient-reported outcomes. Ignaseclant targets the skeletal muscle-specific chloride ion channel 1.

#biotech #CMT #lifescience #PhaseII

NMD Pharma Reports Topline Phase IIa Results

NMD Pharma announced data from the SYNAPSE-CMT study evaluating ignaseclant in Charcot-Marie-Tooth disease types 1 and 2. The CIC-1 inhibitor showed consistent functional improvements regarding muscle strength, motor performance, and patient-reported outcomes. Ignaseclant targets the skeletal muscle-specific chloride ion channel 1.

#biotech #CMT #lifescience #PhaseII

NMD Pharma Reports Topline Phase IIa Results

NMD Pharma announced data from the SYNAPSE-CMT study evaluating ignaseclant in Charcot-Marie-Tooth disease types 1 and 2. The CIC-1 inhibitor showed consistent functional improvements regarding muscle strength, motor performance, and patient-reported outcomes. Ignaseclant targets the skeletal muscle-specific chloride ion channel 1.

#biotech #CMT #lifescience #PhaseII

NMD Pharma Reports Topline Phase IIa Results

NMD Pharma announced data from the SYNAPSE-CMT study evaluating ignaseclant in Charcot-Marie-Tooth disease types 1 and 2. The CIC-1 inhibitor showed consistent functional improvements regarding muscle strength, motor performance, and patient-reported outcomes. Ignaseclant targets the skeletal muscle-specific chloride ion channel 1.

#biotech #CMT #lifescience #PhaseII

NMD Pharma Reports Topline Phase IIa Results

NMD Pharma announced data from the SYNAPSE-CMT study evaluating ignaseclant in Charcot-Marie-Tooth disease types 1 and 2. The CIC-1 inhibitor showed consistent functional improvements regarding muscle strength, motor performance, and patient-reported outcomes. Ignaseclant targets the skeletal muscle-specific chloride ion channel 1.

#biotech #CMT #lifescience #PhaseII

This made me laugh while down in the rabbit hole of #HST #PhaseII documentation:

(“SPARS” is a contraction of the word “sparse.”)

https://hst-docs.stsci.edu/wfc3ihb/chapter-7-ir-imaging-with-wfc3/7-7-ir-exposure-and-readout#id-7.7IRExposureandReadout-7.7.3

#Astrodon

Just imagine if this were real...

#StarTrek #PhaseII Intro

https://www.youtube.com/watch?v=RBy8iMl4SCQ

#Trek #StarTrekPhaseII #StarTrekPhase2 #Phase2 #Paramount #GeneRoddenberry #Disco #SciFi #SciFiTV

Just imagine if this were real...

#StarTrek #PhaseII Intro

https://www.youtube.com/watch?v=RBy8iMl4SCQ

#Trek #StarTrekPhaseII #StarTrekPhase2 #Phase2 #Paramount #GeneRoddenberry #Disco #SciFi #SciFiTV

Just imagine if this were real...

#StarTrek #PhaseII Intro

https://www.youtube.com/watch?v=RBy8iMl4SCQ

#Trek #StarTrekPhaseII #StarTrekPhase2 #Phase2 #Paramount #GeneRoddenberry #Disco #SciFi #SciFiTV